Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-05-09

Clinical Trial Update: Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating defibrotide therapy for COVID-19–related acute respiratory distress syndrome is completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Defibrotide (defibrotide)

Snippet

Sponsor: Gregory Yanik | Conditions: COVID, Sars-CoV2 | Phase 1 | Status: COMPLETED | Results posted: 2023-05-09